DBV Technologies S.A. is a clinical-stage biopharmaceutical company that develops epicutaneous immunotherapy products such as Viaskin Peanut, which has completed Phase III clinical trial for peanut allergy treatment. The company has ongoing trials for Viaskin Milk and Viaskin Egg to treat milk- and egg- induced allergies and is also researching potential treatments for other diseases such as Crohn's disease and type I diabetes. It has a collaboration with Nestlé Health Science to develop MAG1C for the diagnosis of non-IgE mediated CMPA in infants and toddlers.